Genmab A/S (GMAB) KPIs and segments
Close on Nov 18, 2026
KPIs & segments
Operating metrics and segments that drive Genmab A/S's business · fiscal year ends December 31
Genmab A/S KPIs at a glance: 76 operating metrics, including EPKINLY / TEPKINLY Global Net Sales, Genmab Proprietary Net Product Sales and Total Royalty Revenue Earned by Genmab, drawn from 76 source documents, alongside revenue by segment, product and region from SEC filings. Each figure links to the document it came from. All metrics shows the full sheet; Core narrows it to segments and headline KPIs. The segment tables also offer a trailing-twelve-month view.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
Segments, headline KPIs and every operating metric from filings, earnings releases and presentations.
| Add to chart | Metric | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPKINLY / TEPKINLY Global Net Sales (Genmab & AbbVie)($M)3 | 179 | 175 | 137 | 135 | 122 | 121 | 90 | 78 | 82 | 69 | 52 | ||
EPKINLY U.S. & Japan Net Product Sales (Recognized by Genmab)($M) | 139 | 136 | 106 | 107 | 97 | 100 | 75 | 74 | 70 | 62 | 47 | ||
TEPKINLY International Net Sales by AbbVie (Royalty Territory)($M) | 40 | 39 | 31 | 27 | 25 | 21 | 15 | 4 | 12 | 7 | 5 | ||
EPKINLY Collaboration Profit-Sharing Balance Paid to AbbVie($M) | 68 | 66 | 50 | 51 | 46 | 47 | 35 | ||||||
Genmab Proprietary Net Product Sales (EPKINLY & Tivdak)($M)2 | 149 | 145 | 116 | 118 | 104 | 101 | 75 | 74 | 70 | 62 | 47 | ||
Tivdak Japan & Europe Net Product Sales (Recognized by Genmab)($M) | 10 | 9 | 10 | 11 | 7 | 1 | 0 | ||||||
Tivdak Global Net Sales (Genmab & Pfizer Combined)($M) | 47 | 45 | 39 | 42 | 45 | 33 | |||||||
Total Royalty Revenue Earned by Genmab($M)4 | 991 | 966 | 742 | 883 | 841 | 789 | 589 | 715 | 691 | 659 | 452 | ||
DARZALEX / DARZALEX FASPRO Royalty Revenue (from J&J)($M) | 751 | 744 | 562 | 699 | 656 | 638 | 450 | 577 | 557 | 538 | 347 | ||
Kesimpta Royalty Revenue (from Novartis)($M) | 149 | 143 | 116 | 123 | 122 | 108 | 90 | 95 | 84 | 80 | 64 | ||
TEPEZZA Royalty Revenue (from Amgen)($M) | 36 | 31 | 26 | 30 | 30 | 20 | 25 | 28 | 29 | 23 | 26 | ||
Other Marketed Antibody Royalties (RYBREVANT, TECVAYLI, TALVEY & TEPKINLY)($M) | 55 | 48 | 38 | 31 | 33 | 23 | 24 | 15 | 21 | 18 | 15 | ||
DARZALEX Global Net Sales by J&J (Underlying Royalty Base)($M) | 4,239 | 4,207 | 3,964 | 3,903 | 3,672 | 3,539 | 3,237 | 3,084 | 3,016 | 2,878 | 2,692 | 2,550 | |
Kesimpta Global Net Sales by Novartis (Underlying Royalty Base)($M) | 1,484 | 1,424 | 1,164 | 1,228 | 1,222 | 1,077 | 899 | 950 | 838 | 799 | 637 | ||
TEPEZZA Global Net Sales by Amgen (Underlying Royalty Base)($M) | 526 | 576 | 490 | 457 | 560 | 505 | 381 | 460 | 488 | 479 | 424 | ||
Employees at Period-End (FTEs)2 | 3,244 | 3,119 | 3,088 | 3,029 | 2,681 | 2,639 | 2,638 | 2,682 | 2,635 | 2,526 | 2,286 | 2,204 | |
R&D Employees at Period-End (FTEs) | 2,081 | 2,056 | 2,027 | 2,089 | 1,841 | 1,830 | 1,837 | 1,886 | 1,853 | 1,774 | 1,601 | 1,541 | |
SG&A & Commercial Employees at Period-End (FTEs) | 1,163 | 1,063 | 1,061 | 940 | 840 | 809 | 801 | 796 | 782 | 752 | 685 | 663 | |
Approved Antibody Medicines Powered by Genmab Science | 8 | 8 | 8 | 8 | |||||||||
Total Revenue by Collaboration Partner & Product Channel($M)6 | 1,038 | 1,010 | 780 | 940 | 918 | 824 | 640 | 849 | 746 | 717 | 556 | ||
J&J / Janssen Collaboration & Royalty Revenue($M) | 794 | 783 | 592 | 734 | 694 | 656 | 481 | 601 | 575 | 554 | 361 | ||
Novartis Collaboration & Royalty Revenue($M) | 149 | 144 | 117 | 124 | 122 | 109 | 91 | 179 | 84 | 81 | 64 | ||
Roche Collaboration & Royalty Revenue($M) | 36 | 31 | 26 | 30 | 30 | 21 | 25 | 28 | 30 | 23 | 26 | ||
Pfizer Collaboration Profit-Share & Milestone Revenue($M) | 20 | 23 | 16 | 17 | 19 | 22 | 19 | 21 | 19 | 20 | 17 | ||
BioNTech R&D Reimbursement Revenue($M) | 2 | 4 | 0 | 6 | 4 | 11 | 19 | 19 | 34 | 37 | 37 | ||
Direct Net Product Sales & Other Collaboration Counterparties($M) | 27 | 25 | 16 | 7 | 13 | 0 | 2 | 0 | 0 | 0 | 0 | ||
Collaboration Profit-Sharing Revenue (Pfizer Tivdak U.S.)($M)2 | 17 | 22 | 14 | 16 | 17 | 21 | 16 | 17 | 15 | 16 | 14 | ||
R&D Cost Reimbursement Revenue from Partners($M) | 15 | 12 | 8 | 10 | 7 | 13 | 23 | 23 | 39 | 42 | 40 | ||
Development, Regulatory & Commercial Milestone Revenue($M) | 5 | 10 | 16 | 31 | 53 | 1 | 12 | 94 | 1 | 0 | 50 | ||
Full-Year Revenue Guidance — Midpoint (As Issued Each Quarter)($M)8 | 4,425 | 4,425 | 4,230 | 4,230 | 3,600 | 3,600 | 3,500 | ||||||
Full-Year Revenue Guidance — Low End($M) | 4,325 | 4,325 | 4,065 | 4,065 | 3,500 | 3,500 | 3,340 | ||||||
Full-Year Revenue Guidance — High End($M) | 4,525 | 4,525 | 4,395 | 4,395 | 3,700 | 3,700 | 3,660 | ||||||
Full-Year Royalty Revenue Guidance — Midpoint($M) | 3,687 | 3,687 | 3,563 | 3,563 | 3,017 | 3,017 | 2,900 | ||||||
Full-Year Net Product Sales & Collaboration Revenue Guidance — Midpoint($M) | 618 | 618 | 522 | 522 | 445 | 445 | 438 | ||||||
Full-Year Milestones & Reimbursement Guidance — Midpoint($M) | 120 | 120 | 145 | 145 | 138 | 138 | 162 | ||||||
Full-Year Gross Profit Guidance — Midpoint($M) | 4,105 | 4,105 | 3,960 | 3,960 | 3,370 | 3,370 | 3,270 | ||||||
Full-Year Operating Expenses Guidance — Midpoint($M) | -2,880 | -2,880 | -2,810 | -2,810 | -2,140 | -2,140 | -2,140 | ||||||
Full-Year Operating Profit Guidance — Midpoint($M) | 1,225 | 1,225 | 1,150 | 1,150 | 1,230 | 1,230 | 1,130 | ||||||
Common Shares Outstanding at Period-End (Excl. Treasury Shares) | 62,405,855 | 62,353,252 | 64,243,333 | 64,238,408 | 64,206,349 | 64,154,254 | 66,197,244 | 66,187,186 | 66,176,831 | 66,136,909 | 66,122,964 | 66,074,535 | |
RSU Program — Unvested Units Outstanding at Year-End2 | |||||||||||||
RSUs Granted During Period | 13,794 | 15,894 | 625,514 | 6,933 | 14,353 | 3,320 | 633,505 | ||||||
RSUs Vested / Settled During Period | 6,276 | 73,188 | 150,763 | 27,204 | 18,096 | 11,972 | 168,850 | ||||||
Warrant Program — Warrants Outstanding at Year-End2 | |||||||||||||
Warrants Granted During Period | 13,331 | 15,494 | 493,796 | 7,377 | 9,681 | 3,636 | 526,694 | ||||||
Warrants Exercised During Period | 52,603 | 2,531 | 12,313 | 32,059 | 52,095 | 33,863 | 10,058 | ||||||
Receivables Related to Collaboration Agreements($M) | 992 | 969 | 755 | 907 | |||||||||
Trade Receivables Related to Direct Product Sales($M) | 119 | 125 | 106 | 96 | |||||||||
Commercial Inventories (Raw Materials, WIP & Finished Goods)($M) | 30 | 18 | 21 | 18 | |||||||||
Accrued Clinical Trial & External R&D Liabilities($M) | 300 | 340 | 355 | 410 | |||||||||
Payables Related to Collaboration Agreements($M) | 90 | 98 | 81 | 79 | |||||||||
Accrued Bonuses & Staff Cost Liabilities($M) | 141 | 106 | 81 | 171 | |||||||||
Total Contract Liabilities (Deferred Collaboration Revenue)2 | |||||||||||||
Non-Current Contract Liabilities($M) | 82 | 88 | 88 | 95 | |||||||||
Current Contract Liabilities($M) | 19 | 21 | 24 | 24 | |||||||||
Total Goodwill & Intangible Assets (Carrying Amount)($M)4 | 9,197 | 9,227 | 9,303 | 9,478 | |||||||||
Acquired In-Process R&D (Rina-S & Petosemtamab IPR&D)($M) | 8,237 | 8,260 | 8,322 | 8,474 | |||||||||
Acquired Antibody & ADC Technology Platforms($M) | 494 | 498 | 511 | 529 | |||||||||
Goodwill($M) | 355 | 355 | 355 | 355 | |||||||||
Licenses, Commercial Rights & Patents($M) | 111 | 114 | 115 | 120 | |||||||||
Total Merus Acquisition Borrowings (Carrying Amount)($M)4 | 4,992 | 5,135 | 5,208 | 5,274 | |||||||||
Term Loan B Credit Facility (Floating SOFR)($M) | 1,674 | 1,807 | 1,870 | 1,914 | |||||||||
6.250% Senior Secured Notes due 2032($M) | 1,439 | 1,436 | 1,436 | 1,441 | |||||||||
7.250% Senior Unsecured Notes due 2033($M) | 953 | 952 | 952 | 957 | |||||||||
Term Loan A Credit Facility (Amortizing)($M) | 926 | 940 | 950 | 962 | |||||||||
Merus N.V. Total Revenue (Pre-Acquisition)1 | 12,150.00 | 8,828.00 | 26,488.00 | 9,140.00 | 11,772.00 | 7,332.00 | 7,889.00 | ||||||
Merus Collaboration Revenue (Gilead, Incyte, Lilly, Partner Therapeutics) | 11,867.00 | 8,828.00 | 13,148.00 | 9,140.00 | 11,772.00 | 7,332.00 | 7,889.00 | ||||||
Merus N.V. Total R&D Expense (Pre-Acquisition)1 | 80,017.00 | 93,926.00 | 80,116.00 | 74,426.00 | 63,239.00 | 49,119.00 | 38,584.00 | ||||||
Merus Direct External Program R&D Costs3 | 57,355.00 | 72,961.00 | 59,658.00 | 51,696.00 | 45,563.00 | 37,309.00 | 28,500.00 | ||||||
Petosemtamab (MCLA-158, EGFRxLGR5) External R&D Spend | 49,919.00 | 68,967.00 | 48,827.00 | 104,406.00 | 0.00 | 0.00 | 0.00 | ||||||
Zenocutuzumab / BIZENGRI (MCLA-128, HER2xHER3) External R&D Spend | 2,765.00 | -1,916.00 | 7,571.00 | 32,831.00 | 0.00 | 0.00 | 0.00 | ||||||
MCLA-129 (EGFRxc-MET) External R&D Spend | 1,835.00 | 2,942.00 | 848.00 | 15,751.00 | 0.00 | 0.00 | 0.00 | ||||||
Merus General & Administrative Expense | 28,611.00 | 25,252.00 | 22,112.00 | 23,366.00 | 20,765.00 | 22,587.00 | 16,114.00 | ||||||
Merus Operating Loss | -96,478.00 | -110,350.00 | -75,740.00 | -88,652.00 | -72,232.00 | -64,374.00 | -46,809.00 | ||||||
Merus Net Loss | -95,520.00 | -158,218.00 | -96,474.00 | -30,923.00 | -99,905.00 | -50,042.00 | -34,456.00 | ||||||
Merus Cash & Cash Equivalents | 367,491.00 | 442,791.00 | 197,199.00 | 293,294.00 | |||||||||
Merus Current Marketable Securities | 268,441.00 | 267,433.00 | 261,126.00 | 243,733.00 | |||||||||
Cumulative Interventional Clinical Studies Sponsored (Genmab & Merus)7 | 108 | 102 | 99 | 95 | 92 | 89 | 85 | 81 | 77 | 69 | 66 | 65 | |
Phase 3 Sponsored Interventional Studies | 21 | 19 | 17 | 17 | 15 | 14 | 13 | 13 | 11 | 8 | 8 | 7 | |
Phase 2 Sponsored Interventional Studies | 68 | 66 | 65 | 64 | 63 | 61 | 58 | 55 | 54 | 50 | 48 | 48 | |
Phase 1 Sponsored Interventional Studies | 15 | 13 | 13 | 10 | 10 | 10 | 10 | 10 | 9 | 8 | 7 | 7 | |
Epcoritamab Sponsored Clinical Studies | 37 | 34 | 34 | 34 | 33 | 32 | 30 | 27 | 26 | 21 | 19 | 18 | |
Tisotumab Vedotin Sponsored Clinical Studies | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 9 | 9 | |
Rinatabart Sesutecan (Rina-S) Sponsored Clinical Studies | 8 | 8 | 5 | 5 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | |
Petosemtamab Sponsored Clinical Studies | 8 | 6 | 6 | 5 | 5 | 5 | 5 | 5 | 5 | 3 | 3 | 3 | |
Cumulative Planned/Actual Patient Enrollment Across Sponsored Trials6 | 20,258 | 18,502 | 17,572 | 17,270 | 16,414 | 15,250 | 15,123 | 14,355 | 13,531 | 11,645 | 11,573 | 10,478 | |
Phase 3 Sponsored Trial Patient Enrollment | 10,107 | 8,547 | 7,777 | 7,777 | 7,161 | 6,501 | 6,401 | 6,401 | 5,626 | 3,927 | 3,927 | 2,832 | |
Epcoritamab Sponsored Trial Patient Enrollment | 7,187 | 7,103 | 7,103 | 7,103 | 7,031 | 7,009 | 6,983 | 6,218 | 6,192 | 5,649 | 5,598 | 4,503 | |
Tisotumab Vedotin Sponsored Trial Patient Enrollment | 1,622 | 1,622 | 1,622 | 1,622 | 1,622 | 1,622 | 1,522 | 1,522 | 1,522 | 1,522 | 1,522 | 1,522 | |
Rina-S Sponsored Trial Patient Enrollment | 3,910 | 3,910 | 2,980 | 2,980 | 2,196 | 1,536 | 1,536 | 1,536 | 952 | 952 | 952 | 952 | |
Petosemtamab Sponsored Trial Patient Enrollment | 3,545 | 1,985 | 1,985 | 1,985 | 1,985 | 1,985 | 1,985 | 1,985 | 1,985 | 665 | 665 | 665 | |
Acasunlimab Sponsored Trial Patient Enrollment | 764 | 764 | 764 | 764 | 764 | 764 | 763 | 763 | 572 | 572 | 572 | 572 | |
J&J Reported DARZALEX Worldwide Net Sales (U.S. vs. International Split)($M)4 | 4,239 | 4,207 | 3,964 | 3,903 | 3,672 | 3,539 | 3,237 | 3,084 | 3,016 | 2,878 | 2,692 | 2,550 | |
J&J Reported DARZALEX U.S. Net Sales($M) | 2,528 | 2,435 | 2,208 | 2,332 | 2,088 | 2,017 | 1,829 | 1,799 | 1,684 | 1,641 | 1,464 | 1,395 | |
J&J Reported DARZALEX International Net Sales($M) | 1,711 | 1,772 | 1,756 | 1,571 | 1,584 | 1,521 | 1,409 | 1,285 | 1,332 | 1,237 | 1,228 | 1,155 | |
J&J Reported DARZALEX Operational YoY Growth (Constant Currency)(%) | 15.6% | 17.6% | 17.8% | 24.1% | 19.9% | 21.5% | 22.5% | 23.5% | 22.9% | 21.3% | 21.0% | 22.2% | |
J&J Reported DARZALEX Reported YoY Growth(%) | 15.4% | 18.9% | 22.5% | 26.6% | 21.7% | 23.0% | 20.3% | 20.9% | 20.7% | 18.4% | 18.9% | 22.4% | |
J&J Reported RYBREVANT (Amivantamab, DuoBody) Worldwide Net Sales($M)4 | 320 | 289 | 257 | 216 | 198 | 179 | 141 | 122 | 89 | 69 | 47 | ||
J&J Reported RYBREVANT U.S. Net Sales($M) | 201 | 190 | 175 | 146 | 136 | 139 | 113 | 101 | 68 | 52 | 36 | ||
J&J Reported RYBREVANT International Net Sales($M) | 119 | 99 | 82 | 70 | 61 | 41 | 28 | 21 | 21 | 17 | 11 | ||
J&J Reported TECVAYLI (Teclistamab, DuoBody) Worldwide Net Sales($M)2 | 312 | 260 | 202 | 176 | 177 | 166 | 151 | 146 | 135 | 135 | 133 | 126 | |
J&J Reported TECVAYLI U.S. Net Sales($M) | 236 | 186 | 127 | 110 | 115 | 114 | 105 | 108 | 105 | 104 | 101 | 102 | |
J&J Reported TECVAYLI International Net Sales($M) | 77 | 74 | 74 | 66 | 62 | 52 | 46 | 38 | 30 | 30 | 33 | 24 | |
J&J Reported TALVEY (Talquetamab, DuoBody) Worldwide Net Sales($M)2 | 171 | 174 | 152 | 149 | 122 | 106 | 86 | 85 | 75 | 69 | 58 | ||
J&J Reported TALVEY U.S. Net Sales($M) | 112 | 112 | 101 | 105 | 85 | 82 | 68 | 68 | 64 | 59 | 50 | ||
J&J Reported TALVEY International Net Sales($M) | 59 | 62 | 51 | 44 | 37 | 24 | 18 | 17 | 12 | 9 | 8 | ||
Novartis Reported Kesimpta Worldwide Net Sales & Prescription Share Gains($M)4 | 1,484 | 1,424 | 1,164 | 1,228 | 1,222 | 1,077 | 899 | 950 | 838 | 799 | 637 | 641 | |
Novartis Reported Kesimpta Constant-Currency YoY Growth(%) | 22.0% | 32.0% | 26.0% | 27.0% | 44.0% | 33.0% | 43.0% | 49.0% | 28.0% | 65.0% | 66.0% | 73.0% | |
Novartis Reported Kesimpta USD YoY Growth(%) | 21.0% | 32.0% | 29.0% | 29.0% | 46.0% | 35.0% | 41.0% | 48.0% | 28.0% | 63.0% | 66.0% | 74.0% | |
Kesimpta U.S. Overall MS Total Prescription (TRx) Share Gain YoY (pts)(%) | 3.0% | 2.0% | 2.0% | 2.2% | 2.3% | ||||||||
Kesimpta U.S. B-Cell Segment TRx Share Gain YoY (pts)(%) | 4.5% | 2.5% | 1.5% | 2.4% | |||||||||
Spot Exchange Rate: DKK per USD (Period-End, FRED DEXDNUS) | 6.59 | 6.55 | 6.49 | 6.36 | 6.36 | 6.34 | 6.91 | 7.20 | 6.69 | 6.96 | 6.91 | 6.74 | |
Spot Exchange Rate: USD per EUR (Period-End, FRED DEXUSEU)($) | 1.13 | 1.14 | 1.15 | 1.17 | 1.17 | 1.18 | 1.08 | 1.04 | 1.11 | 1.07 | 1.08 | 1.11 | |
Spot Exchange Rate: JPY per USD (Period-End, FRED DEXJPUS) | 157.25 | 162.61 | 159.08 | 156.80 | 147.97 | 144.17 | 149.90 | 157.37 | 143.25 | 160.88 | 151.22 | 140.92 | |
U.S. Producer Price Index: Pharmaceutical Preparation Mfg (BLS PCU325412325412) | 929.30 | 926.20 | 926.00 | 919.30 | 918.70 | 914.80 | 916.50 | 918.50 | 918.10 | 914.00 | 909.00 | 896.40 | |
U.S. Producer Price Index: Biological Product Mfg (BLS PCU325414325414) | 267.20 | 266.30 | 266.30 | 264.10 | 264.10 | 261.90 | 261.90 | 258.30 | 258.00 | 255.20 | 256.80 | 254.50 | |
Consolidated Revenue (USD Presentation Basis)($M)10 | 1,187 | 1,155 | 896 | 1,058 | 1,022 | 925 | 715 | 923 | 816 | 779 | 603 | ||
Cost of Product Sales (USD)($M) | -88 | -84 | -65 | -81 | -58 | -57 | -42 | -48 | -40 | -28 | -27 | ||
Research & Development Expenses (USD)($M) | -451 | -459 | -440 | -521 | -354 | -364 | -359 | -382 | -336 | -361 | -335 | ||
Selling, General & Administrative Expenses (USD)($M) | -196 | -205 | -166 | -208 | -148 | -144 | -126 | -179 | -127 | -129 | -125 | ||
Acquisition & Integration-Related Charges (USD)($M) | -10 | -32 | -45 | -185 | 0 | 0 | 0 | -4 | -3 | -25 | 0 | ||
Total Costs & Operating Expenses (USD)($M) | -756 | -780 | -716 | -1,000 | -563 | -565 | -527 | -613 | -506 | -543 | -487 | ||
Consolidated Operating Profit (USD)($M) | 431 | 375 | 180 | 58 | 459 | 360 | 188 | 310 | 310 | 236 | 116 | ||
Net Financial Items (USD)($M) | -77 | -80 | -106 | -3 | 23 | 63 | 56 | 207 | -57 | 71 | 133 | ||
Consolidated Net Profit (USD)($M) | 342 | 303 | 53 | 31 | 401 | 336 | 195 | 552 | 186 | 203 | 192 | ||
Basic Net Profit per Share (USD)($) | 5.58 | 4.94 | 0.84 | 6.51 | 5.44 | 3.06 | 2.94 | 3.15 | 2.96 | ||||
Diluted Net Profit per Share (USD)($) | 5.51 | 4.91 | 0.83 | 6.46 | 5.42 | 3.05 | 2.92 | 3.13 | 2.94 | ||||
Consolidated Total Assets (USD Presentation Basis)($M)5 | 12,936 | 12,515 | 12,376 | 12,873 | 7,021 | 6,464 | 6,586 | 6,414 | 5,955 | 5,544 | 5,319 | ||
Cash & Cash Equivalents (USD)($M) | 1,860 | 1,503 | 1,521 | 1,715 | 1,761 | 1,296 | 1,619 | 1,380 | 952 | 622 | 2,127 | ||
Marketable Securities (USD)($M) | 0 | 0 | 0 | 0 | 1,650 | 1,603 | 1,607 | 1,574 | 1,648 | 1,637 | 2,163 | ||
Shareholders' Equity (USD)($M) | 6,333 | 5,957 | 5,682 | 5,847 | 5,751 | 5,302 | 5,296 | 5,137 | 4,793 | 4,445 | 4,713 | ||
Net Cash Provided by Operating Activities (USD)($M) | 520 | 51 | 3 | 301 | 536 | 62 | 287 | 389 | 299 | 219 | 219 | ||
Investment in Tangible Assets / CapEx Cash Outflow (USD)($M) | -4 | -2 | -5 | -13 | -2 | -10 | -12 | -14 | -5 | -4 | -4 | ||
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
- Genmab A/S reports on a calendar fiscal year ending December 31 (Q1: Mar 31, Q2: Jun 30, Q3: Sep 30, Q4: Dec 31). Effective January 1, 2025, Genmab changed its presentation currency from Danish Kroner (DKK) to U.S. Dollars (USD) and restated comparative figures.
- Beginning Q3 2026, Genmab separated 'Amortization of acquired intangible assets' (-$14M in FY2025; -$35M in 9M 2026) from R&D expenses on the Consolidated Income Statement; Q4 2025 R&D is derived from full-year and 9M 2025 comparative columns reported on the identical reclassified basis in the Q3 2026 Interim Report.
- On May 21, 2024, Genmab completed the $1.8B acquisition of ProfoundBio (adding Rina-S and Suzhou/Seattle R&D staff). On December 12, 2025, Genmab completed the $8.0B acquisition of Merus N.V. (adding Phase 3 petosemtamab, FDA-approved BIZENGRI, 288 FTEs, and $5.5B of acquisition debt).
- Consolidated year-end and quarterly FTEs include Merus N.V. from Q4 2025 (3,029 FTEs at year-end 2025; 3,244 at Q3 2026), whereas audited ESRS S1 sustainability workforce tables in the FY2025 Statutory Annual Report exclude 288 Merus FTEs pending HR system integration.
Not shown because recent periods are missing (19)
- EPKINLY U.S. Payer Coverage (>97% of commercial and Medicare lives covered on Q3 2026 earnings call) — excluded as a bound/inequality figure rather than an exact point metric
- EPKINLY / TEPKINLY Cumulative Global Regulatory Approvals (>65 approvals across >40 countries on Q2–Q3 2026 earnings calls) — excluded as bound/inequality disclosures
- Clinical Pipeline Count ('over a dozen clinical-stage candidates' / 'more than 20 trials') — excluded as bound wording; exact registered study counts are tracked via NIH ClinicalTrials.gov in Group 9
- Recurring Revenue Share of Total Revenue (96% cited on Q3 2025 earnings call) — disclosed in only a single quarterly call, lacking 3 consecutive periods
- License Revenue ($10M one-off upfront recognition in Q3 2026; $0 in prior periods) — active in only 1 quarter, lacking 3 consecutive periods
- Amortization of Acquired Intangible Assets (separated starting Q3 2026: -$11M in Q3 2026, -$35M in 9M 2026, -$14M in FY2025) — individual Q1 2026 and Q2 2026 quarters were not separately restated
- Quarterly Partner-by-Partner Disaggregation for AMGN, ABBV, and PFE U.S./International Drug Splits — annual Form 10-K regional splits through FY2025 are included in Group 9 while quarterly global totals through Q3 2026 are shown in Groups 1–2
- Pre-2025 DKK Financial Guidance Snapshots — excluded from the USD guidance table due to the January 1, 2025 presentation currency switch from DKK to USD
- Single-Readout Clinical Trial Efficacy Endpoints (e.g., LiGeR-HN1 & EPCORE FL-1 hazard ratios and ORR percentages) — one-time trial event readouts rather than recurring period-by-period operational series
- Parent vs. Consolidated Subtraction for Total Assets, Shareholders' Equity, and Operating Cash Flow — omitted because parent equity investments in subsidiaries ($10,418M in FY2025) and intercompany balances distort subtraction
- Omitted derived XBRL baseline record: Legacy DKK cash-and-short-term-investments: FY2016 (cash-and-equivalents)
- Omitted derived XBRL baseline record: Legacy DKK cash-and-short-term-investments: FY2017 (cash-and-equivalents)
- Omitted derived XBRL baseline record: Legacy DKK cash-and-short-term-investments: FY2018 (cash-and-equivalents)
- Omitted derived XBRL baseline record: Legacy DKK cash-and-short-term-investments: FY2019 (cash-and-equivalents)
- Omitted derived XBRL baseline record: Legacy DKK cash-and-short-term-investments: FY2020 (cash-and-equivalents)
- Omitted derived XBRL baseline record: Legacy DKK cash-and-short-term-investments: FY2021 (cash-and-equivalents)
- Omitted derived XBRL baseline record: Legacy DKK cash-and-short-term-investments: FY2022 (cash-and-equivalents)
- Omitted derived XBRL baseline record: Legacy DKK cash-and-short-term-investments: FY2023 (cash-and-equivalents)
- Omitted derived XBRL baseline record: Legacy DKK cash-and-short-term-investments: FY2024 (cash-and-equivalents)
Data updated 2026-11-11.
Every KPI on its own page
Full history, chart, sources and a citation for each metric
Commercialized Proprietary & Co-Owned Antibody Medicines (Key #1)
Royalty Portfolio & Partnered Antibody Franchises (Key #2)
Workforce Scale, R&D Functional Mix & Clinical Pipeline Spend (Key #3)
- Employees at Period-End (FTEs)31 periods
- Average Employees During Fiscal Year (FTEs)10 periods
- Approved Antibody Medicines Powered by Genmab Science4 periods
- Clinical Stage R&D Expense (Annual Functional Split) ($M)3 periods
- Third-Party Clinical R&D Spend across Antibody Candidates ($M)3 periods
- Total Consolidated Staff Costs ($M)3 periods
Collaboration Partner Matrix & Full-Year Financial Guidance (Key #4)
Share Capital, Equity Incentives, Working Capital, Debt & Facilities
- Common Shares Outstanding at Period-End (Excl. Treasury Shares)26 periods
- Year-End Share Price on Nasdaq Copenhagen10 periods
- Consolidated Equity Ratio (Equity / Total Assets) (%)5 periods
- RSU Program — Unvested Units Outstanding at Year-End4 periods
- Warrant Program — Warrants Outstanding at Year-End4 periods
- Receivables Related to Collaboration Agreements ($M)4 periods
- Trade Receivables Related to Direct Product Sales ($M)4 periods
- Commercial Inventories (Raw Materials, WIP & Finished Goods) ($M)4 periods
- Accrued Clinical Trial & External R&D Liabilities ($M)4 periods
- Payables Related to Collaboration Agreements ($M)4 periods
- Accrued Bonuses & Staff Cost Liabilities ($M)4 periods
- Total Contract Liabilities (Deferred Collaboration Revenue) ($M)3 periods
- Total Goodwill & Intangible Assets (Carrying Amount) ($M)4 periods
- Total Merus Acquisition Borrowings (Carrying Amount) ($M)4 periods
- Copenhagen Global Headquarters — Valby, Denmark (Leased Area)3 periods
International Subsidiaries vs. Genmab A/S Parent Standalone (IFRS)
- International Subsidiaries Year-End Employees (Estimate: Consolidated − Parent)8 periods
- U.S. & Japan Commercial Subsidiaries External Product Sales (Estimate: Consolidated − Parent) ($M)2 periods
- International Subsidiaries Net Revenue Contribution (Estimate: Consolidated − Parent) ($M)2 periods
- International Subsidiaries Operating Result & Eliminations (Estimate: Consolidated − Parent) ($M)2 periods
- International Subsidiaries Cash & Cash Equivalents (Estimate: Consolidated − Parent) ($M)2 periods
Acquired Subsidiary: Merus N.V. (Pre-Acquisition SEC Filings, FY2022–Q3 2025)
Sustainability, Climate (ESRS E1) & Workforce Diversity / Safety (ESRS S1)
- Total Energy Consumption2 periods
- Renewable Electricity & Energy Consumption2 periods
- Renewable Share of Total Energy Consumption (%)2 periods
- Total GHG Emissions — Market-Based (Scopes 1, 2 & 3)2 periods
- ESRS Own Workforce Headcount at Year-End (Excl. Merus in FY2025)3 periods
- Female Representation on Board of Directors (Shareholder-Elected) (%)3 periods
- Female Representation in Senior Leadership / Top Management (%)3 periods
- Unadjusted Gender Pay Gap — Total Workforce (%)2 periods
- Unadjusted Gender Pay Gap — Excluding Executive Management (%)2 periods
- CEO-to-Median Employee Total Compensation Ratio (×)2 periods
- Recordable Work-Related Accidents2 periods
- Total Recordable Incident Rate (TRIR per Million Hours Worked) (×)2 periods
External Clinical Registry (NIH), Partner Drug Filings & Macro FX / PPI
- Cumulative Interventional Clinical Studies Sponsored (Genmab & Merus)106 periods
- Cumulative Planned/Actual Patient Enrollment Across Sponsored Trials106 periods
- J&J Reported DARZALEX Worldwide Net Sales (U.S. vs. International Split) ($M)40 periods
- J&J Reported RYBREVANT (Amivantamab, DuoBody) Worldwide Net Sales ($M)11 periods
- Novartis Reported Kesimpta Worldwide Net Sales & Prescription Share Gains ($M)23 periods
- Amgen Reported TEPEZZA Annual Net Sales by Region (Form 10-K) ($M)5 periods
- AbbVie Reported EPKINLY Annual Net Sales by Region (Form 10-K) ($M)3 periods
- Pfizer Reported Tivdak Annual Net Sales by Region (Form 10-K) ($M)5 periods
- Spot Exchange Rate: DKK per USD (Period-End, FRED DEXDNUS)106 periods
- Spot Exchange Rate: USD per EUR (Period-End, FRED DEXUSEU) ($)106 periods
- Spot Exchange Rate: JPY per USD (Period-End, FRED DEXJPUS)106 periods
- U.S. Producer Price Index: Pharmaceutical Preparation Mfg (BLS PCU325412325412)105 periods
- U.S. Producer Price Index: Biological Product Mfg (BLS PCU325414325414)105 periods
Consolidated Financial Context (USD Restated 2021–2026Q3 & Legacy DKK Baseline)
- Consolidated Revenue (USD Presentation Basis) ($M)11 periods
- Consolidated Total Assets (USD Presentation Basis) ($M)11 periods
- Denmark External Revenue — Royalty & Milestone Hub (USD, Note 2.2) ($M)3 periods
- Weighted-Average Basic Shares (XBRL)9 periods
- Weighted-Average Diluted Shares (XBRL)9 periods
- Revenue (Legacy DKK) (DKK M)8 periods
- Cash & Cash Equivalents (Legacy DKK) (DKK M)9 periods
- Operating Cash Flow (Legacy DKK) (DKK M)8 periods
- Denmark External Revenue (Legacy DKK) (DKK M)8 periods
Latest source documents
The documents cited most often for Genmab A/S's most recent figures
- Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.) ↗
- Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗
- Merus N.V. (Subsidiary, CIK 0001651311) Form 10-Q — Q3 2025 (Ended Sep 30, 2025) ↗
- Merus N.V. (Subsidiary, CIK 0001651311) Form 10-K — FY2024 (Ended Dec 31, 2024) ↗
- NIH ClinicalTrials.gov Registry API v2 — Genmab A/S & Merus N.V. Interventional Studies ↗
- Johnson & Johnson SEC Form 10-K & Form 10-Q Filings (CIK 0000200406) ↗
- Genmab A/S SEC 6-K (filed 2025-02-12, acc. 0001558370-25-000831) ↗
- Federal Reserve H.10 via FRED — Spot FX Rate DKK per USD (DEXDNUS) ↗
- Federal Reserve H.10 via FRED — Spot FX Rate USD per EUR (DEXUSEU) ↗
- Federal Reserve H.10 via FRED — Spot FX Rate JPY per USD (DEXJPUS) ↗
- U.S. Bureau of Labor Statistics via FRED — PPI Pharmaceutical Preparation Mfg (PCU325412325412) ↗
- U.S. Bureau of Labor Statistics via FRED — PPI Biological Product Mfg (PCU325414325414) ↗
See a number that looks wrong?